TCM
ODT

Tang Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Tang Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,767,435
Closed -$17.2M – 60
2021
Q4 		$17.2M Sell
12,767,435
-2,747,131
-18% -$6.5M 3.47% 7
2021
Q3 		$45.1M Hold
15,514,566
– – 9.37% 4
2021
Q2 		$54.1M Hold
15,514,566
– – 10.78% 4
2021
Q1 		$53.1M Hold
15,514,566
– – 14.93% 4
2020
Q4 		$298M Buy
15,514,566
+275,784
+2% +$4.26M 45.48% 1
2020
Q3 		$205M Buy
15,238,782
+1,163,513
+8% +$33M 37.03% 1
2020
Q2 		$596M Hold
14,075,269
– – 57.94% 1
2020
Q1 		$389M Hold
14,075,269
– – 54.57% 1
2019
Q4 		$457M Hold
14,075,269
– – 54.57% 1
2019
Q3 		$366M Hold
14,075,269
– – 62.68% 1
2019
Q2 		$516M Buy
14,075,269
+989,231
+8% +$23.7M 69.79% 1
2019
Q1 		$289M Sell
13,086,038
-961,212
-7% -$16.8M 53.31% 1
2018
Q4 		$198M Buy
14,047,250
+250,503
+2% +$3.9M 45.38% 1
2018
Q3 		$268M Buy
13,796,747
+1,384,409
+11% +$28.2M 43.72% 1
2018
Q2 		$274M Hold
12,412,338
– – 34.74% 2
2018
Q1 		$263M Buy
12,412,338
+210,000
+2% +$4.95M 38.64% 1
2017
Q4 		$305M Buy
+12,202,338
New +$288M 48.33% 1

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Tang Capital Management's ODT Position: Q1 2022 in Review

Tang Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 12,767,435 shares — an estimated $17.2M sold.

Tang Capital Management first reported a position in ODT in Q4 2017 and held it in 17 quarters. The position peaked at $596M in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Tang Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Tang Capital Management sold 12,767,435 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $17.2M.
  • Tang Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
  • Tang Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $596M in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Tang Capital Management's 13F filing for Q1 2022, filed 16 May 2022.